Nuvo strikes deal to acquire Zars; Regulus recruits Pfizer expert as new CSO;

 @FierceBiotech: Galapagos ditches its experimental arthritis drug. Item | Follow @FierceBiotech

 @JohnCFierce: Here's the Reuters story on the tofacitinib RA data for Pfizer. Hard to overestimate importance for Pfizer. Story | Follow @JohnCFierce

> Canada's Nuvo Research has struck a deal to acquire Zars Pharma, a Utah-based developer of pain therapies, for $12.7 million Canadian. Report

> Pfizer oncology expert Neil Gibson, Ph.D., has signed on to become the new chief scientific officer of Regulus Therapeutics. Regulus release

> The FDA has granted Regeneron priority review status for its BLA covering VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration. Release

> BB Biotech is backing Actelion in its fight with Elliott Advisers. "We have never doubted the competence of Actelion's scientists, the commitment of their management or the veracity of their board," said BB Biotech's board. Article

> Valeant and GlaxoSmithKline have filed their response to the FDA's CRL for Ezogabine. Story

Pharma News

> Amgen preps for key investor meeting. Article

> Warner Chilcott plots 500 job cuts in European revamp. Report

> Teva pulls acid reflux tablets after FDA alert. News

> New supplies of scarce cancer drug are coming. Story

> J&J mulls $20B deal for device maker Synthes. Item

Biotech IT News

> Roche informatics guru tackles complex data. News 

> Online brain atlas offers clues about diseases. Article 

> What's driving low enrollment in trials? Report

> "Open source biology" takes center stage. Item 

> Study: Paperless clinical trials offer advantages. News 

Medical Devices News

> Benvenue closes $35.5M round of financing. Report

> Rotation Medical, Dgimed Ortho, raise combined $12.1 million. Story 

> Boston Sci cuts jobs in MN. Article 

> J&J in talks to buy Synthes for $20 billion. News 

> AZ begins Astra Tech auction. Report 

> Medtronic invests $7M in Tengion. Item 

> Lucid files for IPO as it looks to repay debt. Story

And Finally... A new study led by a scientist at Scripps Institution of Oceanography at UC San Diego is painting a more complete picture of an extraordinary sea worm that makes its living in the depths of the ocean on the bones of dead animals. Report